The digital healthcare business of South Korean internet company Kakao Corporation has entered into a collaboration agreement with Dexcom to set up a global digital diabetes management service.
According to a press statement, the deal combines Kakao Healthcare's capabilities in AI and software technology with Dexcom's continuous glucose monitoring (CGM) devices, Dexcom G6 and G7, which the...
Dexcom announced last week that its G7 continuous glucose monitoring system has received FDA clearance.
The latest model of its CGM, which can be used by people with all types of diabetes ages 2 and up, is expected to launch in the U.S. early next year. As the company works out insurance coverage for the G7, it plans to offer cash payment options for early adopters.
The CGM fits on the back of...
At the J.P. Morgan Healthcare Conference this week, Dexcom, maker of continuous glucose monitoring systems, made waves after CEO Kevin Sayer announced new clinical trial data from its yet to be released CGM, the G7.
The 308 person trial demonstrated that the G7's mean absolute relative difference (MARD) was 8.2% for adults and 8.1% for pediatric patients. The G7 was submitted to the FDA in the...
Despite the challenges of 2020, Dexcom was able to close the year out with financial growth for both the fourth quarter and the full year, according to its earnings report released Thursday.
In the earnings call, Dexcom’s chairman, president and CEO Kevin Sayer voiced his gratitude to the company for surpassing its goals even under the extreme circumstances last year.
“In any given year, these...
Dexcom President and CEO Kevin Sayer is “incredibly proud” of what the company is calling “resilient growth” in the second quarter of 2020, according to an earnings call on Tuesday.
Despite having some uncertainty in the impacts of the COVID-19 pandemic, Dexcom was able to produce significant year-over-year growth in Q2 2020.
Sayer attributes much of the growth to a steady increase in knowledge...
When it comes to the diabetes space, Dexcom is one of the heavy hitters. Its work in the continuous glucose monitoring space has put it on the map. In 2018, its Dexcom G6, an integrated continuous glucose monitoring system, got the greenlight from the FDA, making it the first interoperable CGM to get the designation. This means that it could be part of an integrated system compatible with other...
Insulin pump maker Insulin announced partnerships yesterday with two of the leading continuous glucose monitor companies, Abbott and Dexcom. Both involve the Insulet’s Omnipod Horizon Automated Insulin Delivery System which uses a tubeless, wearable “Pod” to deliver insulin for 72 hours at a time.
Abbott and Insulet have partnered to offer a new integrated digital health platform that will...
One of the biggest digital health success stories of the two decades is in the diabetes space, especially the continuous glucose monitor (or CGM). The first CGM was approved by the FDA in 1999, but in the last decade we've seen CGMs become smaller, longer lasting and more comfortable, and we've seen huge strides in datasharing as CGM-phone connectivity went from novelty to commodity.
Dexcom has...
